The U.S. Food and Drug Administration (FDA) has added a so-called “black box” (“boxed warning”) alert to the multiple sclerosis drug Copaxone (glatiramer acetate) and its generic version, Glatopa, because of rare but potentially fatal allergic...

Common MS Drug Causes Rare but Potentially Deadly Allergic Reactions, FDA Warns
The U.S. Food and Drug Administration (FDA) has added a so-called “black box” (“boxed warning”) alert to the multiple sclerosis drug Copaxone (glatiramer acetate) and its generic version, Glatopa, because of rare but potentially fatal allergic...
Mavenclad Effect on Quality of Life
Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis, according to a final analysis of data from a Phase 4 study. Mavenclad is an...
Vidofludimus Calcium Reduced RRMS Brain Lesions in EMPhASIS Trial
by Marisa Wexler, MS | June 17, 2022 Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosis (RRMS), data from the Phase 2 EMPhASIS clinical...